Roivant Sciences Ltd. (ROIV)
Healthcare • Biotechnology
StockNasdaqGSUnited KingdomBMG762791017
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Roivant Sciences Ltd., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 10:36. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 04 Feb 2027 08:00 | -0.31 | — | — | Upcoming |
| 09 Nov 2026 07:00 | -0.45 | -0.18 | +58.9% | Beat |
| 06 Aug 2026 07:00 | -0.36 | -0.34 | +4.9% | Beat |
| 20 May 2026 07:00 | -0.35 | -0.32 | +9.3% | Beat |
| 06 Feb 2026 07:00 | -0.31 | -0.24 | +23.0% | Beat |
| 10 Nov 2025 07:00 | -0.30 | -0.28 | +9.3% | Beat |
| 11 Aug 2025 07:00 | -0.23 | -0.25 | -8.7% | Miss |
| 29 May 2025 07:00 | -0.16 | -0.22 | -33.7% | Miss |
| 10 Feb 2025 07:00 | -0.24 | -0.20 | +17.2% | Beat |
| 12 Nov 2024 07:00 | -0.24 | -0.30 | -23.8% | Miss |
| 08 Aug 2024 07:00 | -0.24 | -0.18 | +25.7% | Beat |
| 30 May 2024 07:00 | -0.29 | -0.23 | +20.1% | Beat |
| 13 Feb 2024 07:00 | -0.27 | -0.21 | +22.3% | Beat |
| 13 Nov 2023 07:00 | -0.27 | -0.29 | -7.1% | Miss |
| 14 Aug 2023 07:00 | -0.28 | -0.28 | -0.7% | In line |
| 28 Jun 2023 07:00 | -0.32 | -0.26 | +21.1% | Beat |
| 13 Feb 2023 07:00 | -0.32 | -0.42 | -30.3% | Miss |
| 14 Nov 2022 08:00 | -0.34 | -0.32 | +3.8% | Beat |
| 15 Aug 2022 07:00 | -0.28 | -0.30 | -6.9% | Miss |
| 28 Jun 2022 06:00 | -0.30 | -0.27 | +10.2% | Beat |
| 14 Feb 2022 07:00 | -0.24 | -0.41 | -71.3% | Miss |
| 15 Nov 2021 07:00 | -0.36 | -0.32 | +11.9% | Beat |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2026 | 8.3M | -71.6% | -299.8M | -3,629.2% | -0.54 | -125.0% | -758.6M |
| 2025 | 29.1M | -11.2% | -172M | -592.0% | -0.24 | -104.6% | -844.1M |
| 2024 | 32.7M | +3.8% | 4.3B | 13,294.2% | 5.23 | +468.3% | -766.7M |
| 2023 | 31.5M | — | -1B | -3,200.2% | -1.42 | — | -856.1M |
| 2022 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 09 Nov 2026 – 12 Nov 2026 In progress | 39.47 | 42.24 | 39.22 | 39.99 | +2.85% | 39,558,300 | |
| 02 Nov 2026 – 06 Nov 2026 | 36.95 | 39.08 | 35.56 | 38.88 | +5.34% | 46,493,500 | |
| 26 Oct 2026 – 30 Oct 2026 | 36.66 | 37.97 | 35.66 | 36.91 | +1.15% | 30,512,900 | |
| 19 Oct 2026 – 23 Oct 2026 | 33.78 | 38.49 | 33.60 | 36.49 | +8.83% | 48,521,000 | |
| 12 Oct 2026 – 16 Oct 2026 | 34.92 | 35.41 | 33.00 | 33.53 | -5.39% | 24,837,300 | |
| 05 Oct 2026 – 09 Oct 2026 | 35.98 | 36.34 | 33.32 | 35.44 | -0.78% | 29,614,100 | |
| 28 Sep 2026 – 02 Oct 2026 | 35.65 | 37.35 | 35.19 | 35.72 | -0.22% | 26,478,600 | |
| 21 Sep 2026 – 25 Sep 2026 | 39.02 | 39.90 | 35.51 | 35.80 | -9.98% | 34,069,400 | |
| 14 Sep 2026 – 18 Sep 2026 | 40.64 | 41.60 | 39.17 | 39.77 | -2.57% | 61,678,600 | |
| 08 Sep 2026 – 11 Sep 2026 | 39.98 | 42.50 | 38.41 | 40.82 | +16.86% | 48,307,900 | |
| 252 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- How Trial Wins And Drug Launch Revenue Will Impact Roivant Sciences Stock (ROIV) (opens in a new tab) Simply Wall St. · 12 Nov 2026 07:14
- Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum (opens in a new tab) SeekingAlpha · 11 Nov 2026 13:27
- Roivant Sciences Ltd (ROIV) (Q2 2026) Earnings Call Highlights: LISRIA Launch Delivers $31 ... (opens in a new tab) GuruFocus.com · 10 Nov 2026 09:02
- HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $48 (opens in a new tab) Benzinga · 10 Nov 2026 07:18
- Roivant Sciences (ROIV) Q2 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 09 Nov 2026 22:13
- Roivant Sciences Q2 Earnings Call Highlights (opens in a new tab) MarketBeat · 09 Nov 2026 17:15
- Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript (opens in a new tab) SeekingAlpha · 09 Nov 2026 16:01
- Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates (opens in a new tab) Zacks · 09 Nov 2026 12:40
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update (opens in a new tab) 09 Nov 2026 12:00
- Roivant Sciences Ltd. 2026 Q2 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 09 Nov 2026 11:02
- Roivant Sciences Q2 2027 Earnings Call Transcript (opens in a new tab) Benzinga · 09 Nov 2026 10:08
- Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years (opens in a new tab) Benzinga · 06 Nov 2026 19:15
- Roivant Sciences (ROIV) Stock Looks Expensive Against Its Book Value (opens in a new tab) Simply Wall St. · 05 Nov 2026 06:13
- Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis Trials (opens in a new tab) TIKR · 23 Oct 2026 18:25
- Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis Results (opens in a new tab) MarketBeat · 21 Oct 2026 16:04
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 41.85 USD
- Market cap
- 29.0B
- Exchange
- NasdaqGS
- Country
- United Kingdom
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
Similar shares
Follow ROIV and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.